P0F Stock Chart & Stats
$0.57
>-$0.01(-0.53%)
―
--
Day’s Range― - ―
52-Week Range$0.36 - $0.67
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
€283.25M
Enterprise Value$2.11K
Total Cash (Recent Filing)€142.50M
Total Debt (Recent Filing)€75.20M
Price to Earnings (P/E)―
Beta-0.67
Next Earnings
Aug 21, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding464,947,240
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.09Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)€35.90M
Bulls Say, Bears Say
Bulls Say
Orphan-disease FocusA dedicated orphan/rare-disease strategy provides structural advantages: regulatory incentives, accelerated pathways and pricing power for successful therapies. These durable features improve commercialization economics and create a clearer long-term value path if clinical programs progress.
Strong Revenue GrowthTTM revenue rising 112% signals improving commercial traction or milestone receipts and a positive top-line trend. Sustained revenue growth over multiple periods helps absorb fixed R&D costs and is a durable indicator that underlying programs or partnerships are beginning to generate repeatable income.
Manageable LeverageA moderate debt-to-equity (~0.30) means the firm is not highly levered, preserving borrowing capacity and lowering near-term bankruptcy risk. This structural flexibility supports continuing clinical development and potential capital raises without immediate solvency pressure.
Bears Say
Severe Cash BurnSustained deeply negative operating and free cash flow (~-265M to -267M TTM) is a persistent structural risk: it rapidly depletes liquidity, forces frequent funding rounds, and increases dilution risk. This undermines long-term investment capacity and operational runway absent new capital.
Highly Loss-makingNet losses many times revenue and a roughly -592% net margin indicate the business is structurally unprofitable. Such deep, persistent losses reduce resilience to setbacks, limit reinvestment from internal cash, and make strategic progress dependent on external funding and successful clinical outcomes.
Capital Erosion & Poor ROEMaterial equity erosion and a ~-98% ROE show capital destruction over recent periods. That reduces the company’s financial buffer, strains investor confidence, and makes future financing costlier or dilutive, impairing long-term strategic optionality and partnership leverage.
Egetis Therapeutics AB News
P0F FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was $0.36 and its highest was $0.67 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is €283.25M.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 25 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Apr 29, 2026. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of -$0.017 by -$0.005.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.01.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -$0.022 in its last earnings report, missing expectations of -$0.017. Following the earnings report the stock price went down -2.33%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in DE:P0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
P0F Stock 12 Month Forecast
Average Price Target
$2.09